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MATERIALS AND
METHODS
Using the RAND/UCLA Appropriateness Method, 12 European urologists established recom-
mendations (BCJ) for the appropriateness of PBx according to the prostate-speciﬁc antigen level,
digital rectal examination ﬁndings, number of previous negative PBxs, prostate volume, and life
expectancy, with and without consideration of the PCA3 scores. These recommendations were
applied to 1024 subjects receiving placebo in the Reduction by Dutasteride of Prostate Cancer
Events trial, including men with a previous negative PBx, a baseline prostate-speciﬁc antigen
level of 2.5-10 ng/mL, and a PCA3 test performed before the protocol-mandated 2- and 4-year
repeat PBxs. Three scenarios (ie, BCJ alone, BCJ with PCA3, and the PCA3 score alone)
were tested for their ability to reduce the repeat PBx rate versus missing Gleason sum 7 prostate
cancer (PCa).RESULTS BCJ with PCA3 would have avoided 64% of repeat PBxs compared with 26% for BCJ alone and
55% for PCA3 alone (cutoff score 20). Of 55 PCa cases (Gleason sum 7), 13 would have been
missed using BCJ alone compared with 7 using PCA3 (cutoff score 20) alone and 8 using BCJ plus
PCA3. The diagnostic accuracy for Gleason sum 7 PCa of the BCJ with PCA3 scenario was
superior to that of the other scenarios, with a negative predictive value of 99%.CONCLUSION Application of the BCJ together with PCA3 testing can reduce the number of repeat PBxs while
maintaining the sensitivity to detect Gleason sum 7 PCa. UROLOGY 81: 998e1004, 2013.
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vier Inc. Open access under CC BY-NC-ND lhe vast majority of prostate cancer (PCa) is
currently diagnosed using transrectal prostateTbiopsy (PBx). The decision to perform a PBx is
usually determined by suspicious ﬁndings on a digital
rectal examination (DRE) and/or an elevated serum
prostate-speciﬁc antigen (PSA) level. The positive
predictive values of DRE (<20%) and serum PSA
(<25%-30% for PSA <10 ng/mL) are relatively low,
such that only 1 in 4 PBxs will reveal PCa.1-3 Of more
concern is that a systematic repeat PBx will reveal cancer
in 10%-35% of those with a previous negative PBx.4-7
This observation, fueled by the anxiety of physicians
and patients of missing signiﬁcant PCa, has created
a shift toward more aggressive diagnostic strategies that
incorporate multiple repeat PBxs.8,9 This ultimately
exposes patients to additional anxiety and complica-
tions, including sepsis, and the risks of a diagnosis of
a low-volume/low-grade “indolent” PCa and receiving
unnecessary radical treatment.100090-4295/13
http://dx.doi.org/10.1016/j.urology.2012.11.069
icense. 
Currently, the decision to perform a repeat PBx relies
on the physician’s best clinical judgment (BCJ) to esti-
mate the patient’s risk of PCa and patient preference. The
BCJ usually incorporates the results of the DRE, the PSA
level and its derivatives, patient age and/or life expec-
tancy, and prostate volume.11 In addition, physicians can
use a novel commercially available biomarker, the pros-
tate cancer gene 3 (PCA3) assay.
The present study evaluated the effectiveness of
physicians’ BCJ for selecting men for a repeat PBx after
a ﬁrst negative PBx and the additional value of the PCA3
assay on such judgment, both in terms of reducing the
number of repeat PBxs and correctly diagnosing Gleason
sum 7 PCa.
MATERIAL AND METHODS
Study Design
The aim of the present study was to measure the effect of the
physician’s BCJ on the PBx and PCa detection rates in a subset of
men from the placebo arm of the Reduction by Dutasteride of
Prostate Cancer Events (REDUCE) trial. To model BCJ, we used
the RAND/UCLA Appropriateness Method. The RAM was
developed in the 1980s to combine the best available scientiﬁc
evidence with the collective judgment of experts to yield
a statement regarding the appropriateness of performing a proce-
dure at the level of patient-speciﬁc symptoms, medical history,
and test results. The RAM approach can guide clinicians needing
to make decisions when deﬁnitive robust scientiﬁc evidence, such
as randomized prospective trials, is lacking. The design and results
of the RAM expert recommendations study have been described
in detail by Tombal et al.12 In brief, 12 European urologists
established recommendations for the appropriateness to perform
a PBx in a systematically constructed set of 108 hypothetical
patient proﬁles. These proﬁles included unique combinations of
clinical variables predicting PCa risk (ie, life expectancy, DRE
ﬁndings, PSA level, prostate volume, number of previous nega-
tive PBxs).12 For each proﬁle, the PBx was classiﬁed as appro-
priate, inappropriate, or uncertain. All patient proﬁles were rated
separately, and a PBx recommendation was given with and
without consideration of the PCA3 score. The panel recom-
mendations were embedded in an electronic tool (the beta
version of which can be viewed at http://tools.e-hims.com/mime/
pca-biopsy).
The RAM expert recommendations (BCJ) were applied to
a cohort of patients from the placebo arm of the REDUCE trial,
an international, multicenter, double-blind, placebo-controlled
trial designed to compare the effect of the 5a-reductase inhibitor
dutasteride to placebo on the detection of PCa. The REDUCE
trial enrolled men with a baseline PSA level of 2.5-10 ng/mL
(age <60 years) or 3-10 ng/mL (age 60 years) and a previous
negative (6-12 core) PBx. Patients were followed up for 4 years
and were scheduled for 2 protocol mandated 10-core PBxs per-
formed at 2 and 4 years after enrollment.13 The present study
used the data from a subset of men from the placebo group of the
REDUCE trial who had had a PCA3 assay, DRE, and PSA
measurement performed before the study-mandated 2- and 4-year
PBxs and with complete data available to allow appropriateness
calculations.13 PCA3 testing on urine samples was done at Caris
Diagnostics/Molecular Proﬁling Institute (Phoenix, AZ).
The analyses were done in 3 phases. First, the appropriateness
of PBx in the study population was assessed for 3 scenarios: BCJUROLOGY 81 (5), 2013without and with the PCA3 score, and the PCA3 score alone
using a cutoff of 20.14 Subsequently, the appropriateness
outcomes were correlated with the actual PBx outcome (nega-
tive vs positive; Gleason sum <7 vs 7 when positive). Finally,
a tradeoff analysis was done, assessing the balance between the
number of inappropriate (“avoidable”) repeat PBxs versus the
number of missed Gleason sum <7 and 7 PCa cases, respec-
tively. For the ﬁrst 2 scenarios, a PBx was considered unneces-
sary for cases rated as “inappropriate” according to the expert
recommendations. For the third scenario, PBx was considered
unnecessary for all cases with a PCA3 score <20. The PCA3
score cutoff of 20 was similar to the lowest cutoff score used in
the RAM analyses12 and was chosen according to the results
from previous European PCA3 studies suggesting that this cutoff
might have the greatest clinical utility.14,15 Because the Food
and Drug Administration (FDA) recently approved the PRO-
GENSA PCA3 Assay with a cutoff score of 25, all outcomes,
where applicable and possible, were also calculated for a cutoff
of 25.
Statistical Analysis
The BCJ was applied to the REDUCE patient data on the basis of
unique proﬁles (combinations of the values of relevant patient
characteristics). The last variable values and corresponding last
PBx results for a given subject were used for all analyses.
The diagnostic properties (sensitivity, speciﬁcity, positive pre-
dictive value, and negative predictive value [NPV]) were calcu-
lated for the BCJ without and with the inclusion of the PCA3
score and the scenario with the PCA3 score alone. All conﬁdence
interval calculations were 2-sided with an a of 0.05. All statistical
analyses were performed using PASW Statistics, release 18.0.
RESULTS
Patient Demographics and Baseline Characteristics
A subset of 1140 subjects from the placebo arm of the
REDUCE study cohort provided urine samples for PCA3
analysis before the 2- and/or 4-year PBx (not study
mandated). The samples from 1072 patients provided
sufﬁcient messenger RNA for PCA3 analysis. Data
allowing appropriateness calculations were complete for
1024 of these men; thus, apart from the PCA3 score, age,
PSA level, DRE ﬁndings, and prostate volume data were
also available. The baseline characteristics of this pop-
ulation are listed in Table 1.
Effect of PCA3 Testing on Decision to Repeat PBx
Figure 1 shows the ﬂow diagrams for BCJ without and
with PCA3 and for the PCA3 score alone. According to
the BCJ, a repeat PBx was inappropriate for 26% of the
men when the PCA3 score was not included in the model
and in 64% of the men when the PCA3 score was
included (Fig. 1A,B). If only the PCA3 score (cutoff
score 20) was considered, PBx was judged inappropriate
in 52% of men (Fig. 1C). For a cutoff score of 25, this was
63%. A strong relationship was found between the BCJ
and actual PBx outcome, particularly when the PCA3
score was included in the model (Fig. 1B). Of the men for
whom a PBx was considered inappropriate when taking
into account the PCA3 score (n ¼ 656), 90% had999
Table 1. Baseline characteristics (n ¼ 1024)
Variable Value
Mean age (y) 65.5  6.0
Mean PSA (ng/mL) 6.4  3.0
Mean prostate volume (cm3) 57.9  25.3
Suspicious DRE (%) 3.5
Positive repeat biopsy (%) 17.9
Positive biopsy with Gleason sum 7 (%) 5.4
DRE, digital rectal examination; PSA, prostate-speciﬁc antigen.
Data presented as mean  standard deviation or percentages.
Men included in the placebo arm of the Reduction by Dutas-
teride of Prostate Cancer Events trial who had complete data for
appropriateness calculations.negative PBx ﬁndings. One percent of the “inappropriate”
cases (n ¼ 8) had Gleason sum 7 PCa, representing
15% of men with Gleason sum 7 PCa (n ¼ 55)
compared to 5% (n ¼ 14 of 267 “inappropriate” cases) if
the PCA3 score was not considered, representing 25% of
men with Gleason sum 7 PCa.Tradeoff Between Risks of PBx and Missed
Signiﬁcant PCa
The tradeoff outcomes for the 3 scenarios compared with
the per protocol-mandated PBxs that were performed in
all men are listed in Table 2. The ﬁrst scenario was
application of the BCJ without consideration of PCA3;
the second was application of the BCJ, including the
PCA3 score; and the third was PBx considered inappro-
priate for men with a PCA3 score <20. The reductions in
the number of PBxs for the 3 scenarios were the
percentage of PBxs that were considered inappropriate in
these scenarios. The number of missed PCa cases repre-
sents the number of men with Gleason sum <7 and 7
PCa for whom PBx was considered inappropriate and,
thus, would have been missed if these scenarios had been
applied in clinical practice. The results show that the
second scenario (BCJ including the PCA3 score) would
have resulted in the greatest reduction in PBxs while
missing fewer Gleason sum 7 PCa cases compared with
the BCJ alone (ﬁrst scenario). The number of missed low-
grade PCa cases was greatest in the second scenario. The
application of the recently approved FDA cutoff of 25 for
the PCA3 assay would have resulted in a PBx reduction
of 63%, similar to that with the second scenario (BCJ plus
PCA3 with a cutoff of 20). The number of missed cancers
(Gleason sum 7 PCa) would have been similar to that
with the scenario of the BCJ alone.Diagnostic Accuracy
The diagnostic properties of the BCJ without and with
the inclusion of the PCA3 score and the scenario of only
the PCA3 score with a cutoff of 20 are listed in Table 3.
The sensitivity, speciﬁcity, positive predictive value, and
NPV of the BCJ including the PCA3 score, for Gleason
sum 7 PCa were superior to those in the scenario
without the PCA3 score. The speciﬁcity and positive
predictive value of the former were also better than those1000for the scenario with PCA3 only with a cutoff of 20; the
sensitivity and NPV were comparable.COMMENT
The present study evaluated the ability of physicians’ BCJ
to select men for a repeat PBx after a ﬁrst negative PBx
and the additional value of the PCA3 test. Our analysis
helps to address the modern conundrum of the indication
for a repeat PBx. The latter has become a major concern,
because the use of repeat PBxs increased dramatically
after several studies reported that PCa can be found in
10%-35% of repeat PBxs.4-9
When making decisions regarding a repeat PBx,
physicians must balance the risk of missing clinically
signiﬁcant PCa against the advantages of avoiding
unnecessary PBxs in terms of cost, discomfort, pain,
anxiety, and the risk of complications and hospitalization
associated with the procedure.16-18 One of the most
serious risks of repeat PBx is the diagnosis of indolent,
low-volume/low-grade PCa, potentially leading to patient
anxiety and overtreatment. Resnick et al10 have shown
an association between the number of PBxs and the
likelihood of detecting Gleason sum <7 PCa in radical
prostatectomy specimens (31.1%, 43.8%, and 46.8% of
patients undergoing 1, 2, and 3 PBxs, respectively).
The PCA3 assay is a novel test, recently approved by
the FDA, that can help physicians in the selection of men
requiring a repeat PBx. The test detects and quantiﬁes in
post-DRE urine samples PCA3 messenger RNA,
a biomarker that, in contrast to PSA, is overexpressed by
PCa cells.19,20 Several studies have shown a relationship
between the PCA3 score and the probability of a positive
initial or repeat PBx.13-15,21,22 The predictive value of the
PCA3 score for a positive repeat PBx is superior to that of
PSA and percent free PSA (%fPSA).14 In the placebo
arm of the REDUCE trial, elevated PCA3 scores were
predictive of positive repeat PBxs.13 The PCA3 scores
measured at year 2 were also predictive of the PBx results
at year 4. In addition, several studies have shown an
association between the PCA3 score and PCa aggressive-
ness, including Gleason sum, tumor volume, percentage
of positive cores, and the presence of histologically
signiﬁcant PCa using the Epstein criteria.13-15,23-25
However, to date, the role of PCA3 in predicting PCa
aggressiveness remains controversial.25
To test the ability of physicians’ BCJ without or with
the PCA3 test to correctly identify men requiring a repeat
PBx, we used the previously established RAM expert
recommendations.12 These recommendations simulate
what a panel of expert clinicians ideally would have done
in real-life clinical practice according to current knowl-
edge, without or with information on the PCA3 score.
The RAM recommendations were projected on the
proﬁles of 1024 men from the placebo arm of the
REDUCE trial to measure their effectiveness in reducing
the number of repeat PBxs and their effect on the detec-
tion of Gleason sum 7 PCa. These patients wereUROLOGY 81 (5), 2013
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Figure 1. Flow diagrams of best clinical judgment (BCJ) models (A) without and (B) with consideration of prostate cancer
gene 3 (PCA3) score and (C) model using PCA3 as sole diagnostic variable with cutoff score of 20. RAM, RAND/UCLA
Appropriateness Method; PCa, prostate cancer.
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Table 2. Outcome tradeoff analysis
Scenario Biopsy (n) Reduction (%)
Missed Gleason
Sum 7 PCa (n)
Missed Gleason
Sum <7 PCa (n)
REDUCE patient arm 1024 — 0 0
BCJ without PCA3 757 26 14 31
BCJ with PCA3 368 64 8 55
PCA3 only, cutoff 20 488 52 7 49
BCJ, best clinical judgment; n, number of patients; PCa, prostate cancer; PCA3, prostate cancer gene 3; REDUCE, Reduction by Dutasteride
of Prostate Cancer Events.
Number of biopsies vs number of missed low-grade and high-grade cancer; number of missed cancers represents number of men with
Gleason sum <7 and 7, respectively, for whom prostate biopsy was considered inappropriate and, thus, would have been missed if these
scenarios had been applied in clinical practice.
Table 3. Diagnostic accuracy of BCJ with and without PCA3 and PCA3 only as diagnostic marker
Scenario Sensitivity Speciﬁcity PPV NPV
Any PCa
BCJ without PCA3 75 (68-81) 26 (23-30) 18 (16-21) 83 (78-87)
BCJ with PCA3 66 (58-72) 71 (67-74) 33 (28-38) 90 (88-92)
PCA3 alone, cutoff 20 69 (62-76) 57 (54-60) 26 (22-30) 90 (87-92)
Gleason sum 7
BCJ without PCA3 75 (61-85) 26 (23-29) 5 (4-7) 95 (91-97)
BCJ with PCA3 85 (73-93) 67 (64-70) 13 (10-17) 99 (98-99)
PCA3 alone, cutoff 20 87 (75-94) 55 (51-58) 10 (7-13) 99 (97-99)
NPV, negative predictive value; PPV, positive predictive value; other abbreviations in Table 2.
Data presented as % (95% CI).representative of the entire REDUCE population in terms
of mean age, PSA level, and prostate volume.26,27 PCa was
detected in 183 men included in the analysis (18%);
55 men (5%) had Gleason sum 7 PCa.26 The present
study incorporated patients who underwent 2 protocol-
mandated repeat PBxs within a 4-year period. This situa-
tion differs from real-life practice in which the repeat PBx
is not mandated but determined using available clinical
variables and BCJ on an individual basis, also taking into
account the patient’s anxiety and willingness to avoid
a PBx. The REDUCE setting illustrates a very aggressive
scenario but limited the effect of a veriﬁcation bias.
The results of the present analysis suggest that, overall,
physicians perform poorly when using BCJ alone, because
it only reduced the rate of repeat PBx by 26% but they
missed 14 of 55 of the Gleason sum 7 PCa cases. The
performance of PCA3 alone was strikingly better at
a predeﬁned cutoff score of 20, as suggested in the Euro-
pean PCA3 repeat PBx study.14,15 PCA3 reduced the rate
of repeat PBxs by 52% and missed only 7 of 55 Gleason
sum 7 PCa cases. At a cutoff score of 25, which was
recently approved by the FDA, the PCA3 test would not
have missed more Gleason sum >7 PCa cases than BCJ
alone and would have avoided 63% of the repeat PBxs.
Similarly, PCA3 outperformed the BCJ in reducing the
overdiagnosis of indolent PCa (Gleason sum <7 and PSA
level 2.5-10 ng/mL) by avoiding PBx in 49 such cases
versus 31 cases with BCJ alone. The best risk/beneﬁt ratio
was obtained by combining BCJ with the PCA3 score. In
the latter scenario, 64% of the PBxs would be avoided
while maintaining the sensitivity to detect Gleason
sum 7 PCa. PCA3 increased the NPV for Gleason1002sum 7 PCa of the BCJ from 95% to 99%. The ﬁnding
that most of the repeat PBxs that were considered inap-
propriate were indeed unnecessary and could have been
avoided is critically important to reassure physicians and
patients afraid of missing Gleason sum 7 PCa.
In addition to the effect on healthcare usage, avoiding
unnecessary repeat PBxs will reduce the discomfort, pain,
and other complications associated with PBxs.16-18,28 A
recent survey on a very large sample of men from the
Surveillance, Epidemiology and End Results program has
shown a signiﬁcantly greater risk of hospitalization within
30 days for patients who underwent a PBx than in
a control population and a signiﬁcantly increased risk of
infectious complications requiring hospitalization after
PBx in recent years (both P ¼ .001).18 The latter might
be because of an increasing prevalence of multidrug-
resistant organisms.
The case for reducing overtreatment by limiting the
diagnosis of “indolent” cancer is more controversial. This
strategy is equivalent to “blind active surveillance,”
primarily avoiding the anxiety of the patients, but with
little space for correct appreciation of PCa aggressiveness.
The exact deﬁnition of indolent PCa is not universal. For
analytical purposes, we deﬁned indolent as a PSA level of
2.5-10 ng/mL (as deﬁned in the REDUCE trial protocol)
and a Gleason sum <7 but without considering the
extent of PCa invasion on the PBx. In any case, our
results suggest that when using BCJ alone, physicians
perform poorly in terms of reducing the overdiagnosis of
indolent PCa. Again, combining BCJ and PCA3 testing
was the best strategy to reduce the overdiagnosis of
indolent PCa (55 vs 31). Using the PCA3 score onlyUROLOGY 81 (5), 2013
(cutoff of 20) would have resulted in a similar number of
missed Gleason sum <7 PCa cases.
The most important limitation of our analysis was the
theoretical nature of the work. Another limitation was
the decision not to incorporate %fPSA as a clinical
variable in the decision tree. Although %fPSA is 1 of the
oldest available biomarkers to complement PSA, its value
in repeat PBxs has not been extensively studied, and, to
date, it has not been incorporated in published nomo-
grams.29 A recent study by Auprich et al30 compared the
performance of total PSA, %fPSA, and PCA3 at the ﬁrst,
second and third or more repeat PBxs. PCA3 demon-
strated the greatest diagnostic accuracy and potential
to reduce unnecessary PBxs at the ﬁrst repeat PBx, and
the %fPSA performed best at the second and third or
more repeat PBx.30CONCLUSION
The present results suggest that BCJ alone is fairly inef-
fective for selecting patients requiring a repeat PBx after
a ﬁrst negative PBx, because it only moderately reduces
the PBx rate and misses a signiﬁcant proportion of
Gleason sum 7 PCa. In the decision to repeat a PBx,
the optimal algorithm should include both BCJ and
PCA3 testing, because this combination offers the
greatest reduction in the PBx rate while maintaining the
sensitivity to detect Gleason sum 7 PCa.
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EDITORIAL COMMENT
Determining when a repeat PBx is necessary is a difﬁcult
decision that urologists must often make. This is because the
PSA level becomes even more confounded by benign condi-
tions such as benign prostatic hyperplasia after a negative PBx.1
This report2 addresses the problem by examining how PCA3,
a newly approved biomarker for PCa risk evaluation, can
improve on clinical decision-making in the setting of a previous
negative PBx.
The primary endpoint of the study was to compare the BCJ,
PCA3, and the combination of the 2, to determine whether
a repeat PBx was warranted. To create the BCJ, the authors
presented 12 European urologists with a series of clinical
scenarios, with and without PCA3, and asked them to make
a recommendation for PBx. In effect, this created an algorithm
using the DRE ﬁndings, PSA level, prostate volume, and
previous negative PBxs that incorporated their clinical judg-
ment. The present study then applied this algorithm to subjects
from the placebo arm of the REDUCE trial,3 which conve-
niently provided a well-characterized cohort of men with
a previous negative PBx.
Demonstrated nicely in their study is that clinical judgment,
when combined with PCA3, decreased the uncertainty of
whether a repeat PBx was necessary. The authors divided the
study cohort into 3 categories (PBx appropriate, inappropriate,
or uncertain). Using the clinical judgment algorithm alone,
60% were thus classiﬁed as “uncertain.” With the addition of
PCA3, 38% moved from “uncertain” to “PBx inappropriate.”
Furthermore, the NPV for the detection of any PCa and for
high-grade PCa increased with the addition of PCA3 to the
clinical judgment, despite the need for fewer PBxs.1004Although this study illustrates why PCA3 is exciting in its
possibilities to decrease the morbidity and expense of repeat
PBx, one must remember the limitations of the analyses. This
particular clinical judgment algorithm was based on a small
group of experts from Europe. Decisions by this group of urol-
ogist might or might not represent one’s own individual clinical
judgment; hence, a repeat study using different urologists might
arrive at different conclusions. Another consideration is that
the men enrolled in the REDUCE trial had a limited PSA
range (2.5-10 ng/mL) and a single negative PBx. Therefore,
this study cannot be translated to men with PSA values outside
of that limited data range or who have not had a previous
negative PBx.
This study demonstrates how the addition of PCA3 can
enhance the typical clinical judgment when deciding whether
a repeat PBx is necessary in a given population without an
increase in missed high-grade PCa. Just as with all new
biomarkers, we expect that time and experience in clinical
practice will ultimately dictate the value to providers and
patients.
Rebekah Beach, M.D., and John T. Wei, M.D., M.S.,
Department of Urology, University of Michigan, Ann Arbor,
Michigan
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